Key result
Low-molecular-weight heparins are recommended as the standard of care for the prophylaxis and treatment of cancer-associated thrombosis, effectively reducing venous thromboembolism recurrence.
Why the study?
Do heparins (particularly LMWHs) effectively and safely prevent and treat venous thromboembolism in patients with cancer?
Do heparins (particularly LMWHs) effectively and safely prevent and treat venous thromboembolism in patients with cancer?
This review highlights that low-molecular-weight heparins are the preferred agents for both the prophylaxis and long-term treatment of cancer-associated venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Supports LMWH preference for cancer VTE; leaves open prognostic effects and long-term product variability.
Krasiński et al. (2016) conducted a review in Cancer-associated venous thrombosis. Low-molecular-weight heparins (LMWHs) vs. Unfractionated heparin, oral anticoagulants, or placebo was evaluated. Low-molecular-weight heparins are recommended as the standard of care for the prophylaxis and treatment of cancer-associated thrombosis, effectively reducing venous thromboembolism recurrence.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: